Our Work

Estimating the benefits of reduced fracture incidence for patients living with osteogenesis imperfecta and for healthcare payers

Estimating the benefits of reduced fracture incidence for patients living with osteogenesis imperfecta and for healthcare payers

PICO consolidation in European HTA scoping: Examining PICO variations in oncology drugs in the context of the European Joint Clinical Assessment

PICO consolidation in European HTA scoping: Examining PICO variations in oncology drugs in the context of the European Joint Clinical Assessment

Investigating the influence of therapy-related factors on reimbursement success: A multi-country analysis

Investigating the influence of therapy-related factors on reimbursement success: A multi-country analysis

Estimating the burden of osteogenesis imperfecta on patients and healthcare payers: A health economic modelling study

Estimating the burden of osteogenesis imperfecta on patients and healthcare payers: A health economic modelling study

Conceptualisation and validation of a health economic model for osteogenesis imperfecta

Conceptualisation and validation of a health economic model for osteogenesis imperfecta

ATMP reimbursement: A targeted review of global HTA trends

ATMP reimbursement: A targeted review of global HTA trends

A targeted review of NICE, CADTH and ICER assessments: An evaluation of the Joint Position Statement

A targeted review of NICE, CADTH and ICER assessments: An evaluation of the Joint Position Statement

A comparison of NICE timelines for Highly Specialised Technology submissions and resubmissions

A comparison of NICE timelines for Highly Specialised Technology submissions and resubmissions

“Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer” (Carrato et al); Future Oncology, 2021

Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer

“First- and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe“ (Taieb et al); ESMO Open, 2020

First- and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe

Baseline characteristics for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line (1L) FOLFIRINOX, gemcitabine+nab-paclitaxel (GEM-NAB) or gemcitabine-monotherapy (GEM) treatment (tx) – (ESMO GI; Sociedad Española de Oncología Médica, SEOM 2018) – Patient Chart Audit

Baseline characteristics for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line (1L) FOLFIRINOX, gemcitabine+nab-paclitaxe

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review; (Buske et al. The Lancet Hematology, July 2018

Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review; (Buske et al. The Lancet Hematology, July 2018

Variation of symptoms reported at initial diagnosis of (metastatic) pancreatic adenocarcinoma ([m]PAC) in routine clinical practice across Europe - (Poster, ESMO GI 2018) – Patient Chart Audit

Variation of symptoms reported at initial diagnosis  of (metastatic) pancreatic adenocarcinoma ([m]PAC) in routine clinical practice across Europe - (Poster, ESMO GI 2018) – Patient Chart Audit

Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey. European Journal of Cancer Care, 2016

Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes

Quantitative market research to identify factors that influence chemotherapy-induced nausea and vomiting (CINV) treatment compliance. MASCC / ISOO Annual Meeting 2016. Poster presentation

Quantitative market research to identify factors that influence chemotherapy-induced nausea and vomiting (CINV) treatment compliance.

Identification of factors influencing chemotherapy-induced nausea and vomiting (CINV) treatment compliance. Journal of Clinical Oncology (ASCO) 2016– results from quantitative market research

Identification of factors influencing chemotherapy-induced nausea and vomiting (CINV) treatment compliance.

Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia 57th ASH Annual Meeting and Exposition, 2015, Orlando, FL

Pan-European Data Platform for Treatment and Outcome Patterns in Patients with Waldenstrom's Macroglobulinemia 57th ASH Annual Meeting and Exposition, 2015, Orlando, FL

HER2 testing in BCC: quality assessment, false positives &amp; negatives, quality control. BICE - Best Possible Care in Breast Cancer - Consensus Workshop in Bologna, SIAPEC &amp; AIOM

Let us light your way

UK

Germany

Our Work

Estimating the benefits of reduced fracture incidence for patients living with osteogenesis imperfecta and for healthcare payers

PICO consolidation in European HTA scoping: Examining PICO variations in oncology drugs in the context of the European Joint Clinical Assessment

Investigating the influence of therapy-related factors on reimbursement success: A multi-country analysis

Estimating the burden of osteogenesis imperfecta on patients and healthcare payers: A health economic modelling study

Let us light your way

UK

Germany